

## Endocrinologic and Metabolic Drugs Advisory Committee #74

Food and Drug Administration  
Center for Drug Evaluation and Research

Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda MD

**May 19, 2000**

a presentation of the data and rationale for the regulatory action regarding the withdrawal from the U. S. market of **Rezulin J** , (**troglitazone**, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) for the treatment of type 2 diabetes mellitus.

### Agenda

- 10:00 Open Public Hearing
- 11:00 FDA Presentation: Murray M. Lumpkin, M.D.  
Deputy Center Director for Review Management
- 12:00 Lunch
- 1:00 Parke Davis Pharmaceutical Presentation: Peter B. Corr, Ph.D.  
President, Warner Lambert/Parke Davis  
Pharmaceutical Research and Development
- 1:30 Comments
- 2:00 Adjourn